BRCA1 and cancer: As it has been shown that treatment with PARP inhibitor Olaparib enables to induce BRCA1 foci formation in human cancer cells,48 we next examined whether depletion of USP9X could affect Olaparib induced the formation of BRCA1 foci using immunofluorescent staining.